Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Massive R&D costs, milestone-based collaboration agreements, and nuanced clinical data make BiomX’s SEC disclosures tough to navigate. Whether you’re estimating cash runway for its phage therapy pipeline or tracking how BOLT-enabled programs move through trials, the detail buried in each filing can feel impenetrable.
Below you’ll find direct links—updated in real time—to every form the company submits to EDGAR, plus answers to the exact questions investors type into search bars:
- BiomX insider trading Form 4 transactions
- BiomX quarterly earnings report 10-Q filing
- BiomX Form 4 insider transactions real-time
- BiomX SEC filings explained simply
- BiomX earnings report filing analysis
- understanding BiomX SEC documents with AI
- BiomX executive stock transactions Form 4
- BiomX annual report 10-K simplified
- BiomX proxy statement executive compensation
- BiomX 8-K material events explained
Stock Titan’s AI-powered summaries translate complex biotech language into clear insights, flagging pivotal 8-K events, spotlighting R&D spend in each 10-Q, and highlighting insider buying the moment a Form 4 posts. You’ll quickly see how trial milestones affect projected cash burn, compare quarter-over-quarter expenses, and review executive compensation without wading through technical jargon. Every filing�10-K, 10-Q, S-1, or Form 4—is indexed the moment it hits the SEC, and our expert annotations point you to the sections that matter most for an early-stage microbiome company. Save hours and make sharper decisions with AI that keeps pace with BiomX’s science-driven journey.
Morgan Stanley and subsidiary Morgan Stanley & Co. LLC filed a Schedule 13G (event date 06/30/25, signed 08/05/25) disclosing passive ownership of 1,854,032 BiomX Inc. (PHGE) common shares (CUSIP 09090D301). The position equals 7.1 % of the outstanding class, crossing the 5 % reporting threshold. Both filers report 0 sole voting/dispositive power and shared voting & dispositive power over all shares, indicating the stake is managed collectively across Morgan Stanley reporting units. The filing is made under Rule 13d-1(b) as a qualified institutional investor; Morgan Stanley is classified as HC, CO and the broker-dealer unit as BD, CO.
The certification states the shares were acquired in the ordinary course and not to influence control. No transactions, price data, or strategic intent beyond passive ownership are provided. Nonetheless, disclosure of a large institutional holder may improve liquidity and signal market confidence in BiomX’s prospects.
BiomX Inc. (NYSE American: PHGE) filed a Form 8-K to disclose administrative details for its 2025 Annual Meeting of Stockholders.
- Meeting date: Thursday, October 16, 2025
- Record date: Close of business August 22, 2025
- Shareholder proposal deadline: 5:00 p.m. ET, August 15, 2025 (per Rule 14a-8)
The disclosure is required because the meeting date moves more than 30 days from last year’s meeting, resetting SEC and bylaw timelines. No financial results, transactions, or leadership changes were reported.
OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP L.P., Carl L. Gordon and Erez Chimovits filed Amendment No. 6 to their Schedule 13D on BiomX Inc. (ticker PHGE). The amendment is an exit filing that discloses the group has fallen below the 5% ownership threshold.
Key details:
- On 18 June 2025, OrbiMed Israel Partners ("OIP") sold 1,787,767 common shares of BiomX at $0.34 per share.
- After the sale, the group’s beneficial holdings consist solely of 276,150 shares (all issuable upon conversion of 223 Series X Non-Voting Convertible Preferred Stock and 2,538,500 warrants).
- This position represents 1.0% of BiomX’s 26.45 million shares outstanding (including the shares underlying the preferred stock and warrants).
- The filing emphasises that, as of 18 June 2025, the reporting persons are no longer beneficial owners of more than 5% of BiomX’s outstanding shares.
- The investment committee comprising Gordon and Chimovits continues to review the position and may buy or sell additional shares based on market conditions, but no specific future plans were disclosed.
Implications: The disposal of nearly 1.8 million shares by a long-standing institutional holder removes a significant block from the shareholder register and may affect market perception of insider confidence. However, the remaining warrants and preferred shares ensure the group still retains some exposure to BiomX’s future performance.